Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study
    Meeting Abstract

    Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparable survival of treatment naive TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Shallis, R. M.; Patel, A. A.; Correia, G. S. D. C.; Goldberg, A. D.; Saliba, A.; Bewersdorf, J. P.; Duvall, A. S.; Bradshaw, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical implications of TP53 mutations/allelic state in patients (Pts) with myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA)- a multicenter, retrospective analysis from the VALIDATE database
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study
    Meeting Abstract

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, R. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Loss of CCAAT-enhancer binding protein delta promotes acute myeloid leukemia cell proliferation and survival by upregulating cyclin D1 expression
    Meeting Abstract

    Prajapati, S.; Meydan, C.; Dillon, R.; Dunham, N.; Fan, H.; Gandara, J. A.; Lee, T.; Neelamraju, Y.; Wang, Z.; Zumbo, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HMGA1 chromatin regulators drive immune evasion in MPN progression through epigenetic rewiring to repress antigen presentation
    Meeting Abstract

    Kim, J.; Supreme, A. A.; West, B.; Antopia, M. C.; Reddy, K.; Cope, L.; Kim, J. H.; Rampal, R. K.; Koche, R.; Spivak, J. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • I-DATA Study: Randomized, sequential, open-label study to evaluate the efficacy of IDH targeted/non- targeted versus non-targeted/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated adult AML patients not candidates for intensive induction therapy
    Meeting Abstract

    Ozga, M. P.; Dvorak-Kornaus, K. M.; Zhao, Q.; Buss, J.; Laganson, A.; Hamp, E.; Madanat, Y. F.; Pollyea, D. A.; Stein, E. M.; Zeidner, J. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Johnson, M. F.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Itacitinib for the prevention of immune effector cell therapy-associated cytokine release syndrome: Results from the phase 2 INCB 39110-211 placebo-controlled randomized cohort
    Meeting Abstract

    Frigault, M. J.; Maziarz, R. T.; Park, J. H.; Lazaryan, A.; Shah, N. N.; Svoboda, J.; Lekakis, L. J.; Reshef, R.; Phillips, C. L.; Burke, L. M.; more...
    Blood (2023)

    Fulltext@MSK | Save